ACR Journals On Air
In this episode, Drs. Nilasha Ghosh and Anne Bass discuss immune-related adverse events from immune checkpoint inhibitors, focusing on psoriasis and psoriatic arthritis. They review early clinical recognition, epidemiology, and findings from a multicenter observational study evaluating apremilast, including patient characteristics, outcomes, and key limitations. The conversation also highlights insights from the HSS Checkpoint Inhibitor–Associated Arthritis Registry, the need for greater precision in rheumatology, and practical perspectives on mentorship and career development for emerging...
info_outlineACR Journals On Air
In this episode, Dr. Katie McMenamin and Dr. Josh Baker discuss their research on the genetic drivers of pain in rheumatoid arthritis, drawing on data from the FORWARD and VARA cohorts. They explore how genetic risk scores relate to pain and disease activity, and what these findings mean for patient care, remission, and future clinical trials. The conversation also highlights key study limitations, along with reflections on the research process and advice for trainees pursuing careers in rheumatology.
info_outlineACR Journals On Air
In this episode, Dr. Shervin Assassi discusses a secondary analysis of the SENSCIS trial, exploring how peripheral blood gene expression may predict response to mycophenolate in systemic sclerosis–associated lung disease. He highlights key findings linking immune and metabolic gene signatures, as well as C-reactive protein, to changes in lung function, and considers their potential role in guiding treatment and clinical trial design. The episode also touches on his career journey and insights into leadership, mentorship, and sustaining research productivity.
info_outlineACR Journals On Air
In this episode, we speak with Dr. Sasha Bernatsky about her research on the relationship between exposure to fine particulate air pollution and the development of systemic autoimmune rheumatic diseases. She explains what fine particulate matter is, how her team used large population datasets to study environmental exposures, and what their findings suggest about the potential health impacts of air pollution. The conversation also explores the challenges and limitations of studying environmental risk factors, what comes next for this line of research, and Dr. Bernatsky’s reflections on...
info_outlineACR Journals On Air
In this episode, Dr. Elizabeth Volkmann discusses emerging research on the gut microbiome in systemic sclerosis, building on findings from early-diagnosis and prior microbiome studies. She explains her team’s analysis of microbiome-derived metabolites, including short-chain fatty acids, and their potential role in symptom development, highlighting key findings, clinical implications, and study limitations. The conversation also touches on holistic patient care, international collaboration, and her perspective on the future of systemic sclerosis research and treatment.
info_outlineACR Journals On Air
In this episode, Dr. Madeline O’Sullivan discusses her retrospective study of U.S. veterans in the Veterans Health Administration, examining outcomes among patients with rheumatoid arthritis treated with immune checkpoint inhibitors for cancer. She explains how the cohorts were defined, how use and timing of immunosuppressive therapies were analyzed, and how mortality and cause of death were determined. Dr. O’Sullivan summarizes the patient population, cancer types represented, and key findings on survival differences between RA and non-RA groups, as well as insights from secondary...
info_outlineACR Journals On Air
In this episode, we speak with Dr. Jayne MacMahon about an international collaborative study in juvenile dermatomyositis (JDM) involving pediatric rheumatology centers in Genoa, Italy, and Toronto, Canada. She discusses the study’s motivation, key disease activity measures, treatment targets, and definitions of remission, along with major findings on time to remission, steroid exposure, and treatment outcomes across cohorts. Dr. MacMahon also reflects on the study’s limitations, future research directions, her career path in pediatric rheumatology, and how...
info_outlineACR Journals On Air
In this episode, we sit down with Dr. Evelyne Vinet about a new study examining whether TNF inhibitors increase the risk of serious infections during pregnancy among women with chronic inflammatory diseases. Using large real-world data from the MarketScan database, the discussion explores how pregnancy, inflammatory disease, TNF inhibitor exposure, and serious infections were defined, how confounders were addressed, and what the data reveal across pregnancy and the postpartum period. Dr. Vinet also reflects on study limitations, the impact of COVID-19, and her...
info_outlineACR Journals On Air
In this episode, we explore why rheumatoid arthritis matters to the broader public, with a focus on difficult-to-treat RA (D2T-RA)—what it is, how often it occurs, and why early identification is critical. Our guest demystifies common RA research terms and outcome measures, introduces the real-world data sets behind the study, and explains—in plain language—how a predictive model was developed using modern statistical tools. We discuss the key risk factors for D2T-RA, including which findings were surprising, as well as the study’s major strengths and limitations. The conversation...
info_outlineACR Journals On Air
In this episode, we speak with a leading investigator in large-vessel vasculitis, Dr. Anne Bull Haaversen, to clarify the full spectrum of giant cell arteritis (GCA), including its aortic involvement. We reviewed the prevalence of GCA-related aneurysms, why the team compared ultrasonography with other imaging modalities, and how the ascending aorta can be assessed with ultrasound. Our Dr. Haaversen summarizes the study design, key findings, and limitations, and reflects on how these results may inform future guidelines. We close by discussing the evolution of their research focus on...
info_outlineIn this episode, our host is joined by Dr. Peter Nigrovic, an expert in Macrophage Activation Syndrome (MAS). Dr. Nigrovic, delves into the complexities of MAS. The discussion covers the syndrome's history, diagnostic challenges, mechanisms of inflammation, and the latest treatment strategies, including cytokine blockade, JAK inhibitors, and chemotherapy options. Dr. Nigrovic also reflects on his unique career journey, offering valuable insights into combining clinical practice and research, while sharing his philosophy for a fulfilling life in medicine and science. This episode is a thorough exploration of MAS and provides practical advice for clinicians dealing with this complex syndrome. Macrophage Activation Syndrome